A hybrid family office and operating company based can make investments ranging from $500k-100M into companies, and due to its funding structure, has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes opportunistic and strategic investments, and does not have a target minimum or maximum number of investments for any given year.
The firm is primarily looking for companies in the Therapeutics sector and is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of ophthalmology, dermatology, diabetes, oncology, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are clinical stage, but also capable of supporting companies nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies.
The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management and product development.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment